NEW YORK , June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors...
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the...
NEW YORK , June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors...
TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and rare...
2 S&P 500 Stocks with Solid Fundamentals and 1 We Find Risky
/Vertex%20Pharmaceuticals%2C%20Inc_%20HQ%20in%20Boston-by%20Tada%20Images%20via%20Shuttershock.jpg)
Despite Vertex Pharmaceuticals' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.
/Regeneron%20Pharmaceuticals%2C%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Regeneron Pharmaceuticals has underperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.
